By antagonising the immune-suppressive interaction between PD-1, a T-cell co-inhibitory receptor, and its ligand PD-L1, therapeutic antibodies against this pathway can restore an efficacious anti-tumor immune response, manifest as durable clinical responses in a proportion, but not all patients.11 This evidence concerns the gene CD274 and neoplasm.